Biokeys Pharmaceuticals Inc. Announces Additional HIV/AIDS Cell Mediated Immunity Vaccine Patent
SAN DIEGO--(BW HealthWire)--July 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled ``Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome'' has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlinghaus, Ph.D., currently Chair of the Department of Molecular Pathology at The University of Texas M. D. Anderson Cancer Center and formerly Director of Vaccine Development at the Johnson and Johnson Inc. (NYSE:JNJ - news) R.W. Johnson Biotechnology Research Center in La Jolla, Calif. Biokeys Pharmaceuticals Inc. is the exclusive worldwide licensee of this patent and a portfolio of patents and patent applications covering Dr. Arlinghaus' discoveries crucial to the development of a Cell Mediated Immunity vaccine for HIV Infection/AIDS.
Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses its energy in cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. The Company's lead compound, CoFactor(TM), is a chemotherapy biomodulator designed to be used in conjunction with 5-FU, the world's most frequently used cancer drug. CoFactor is being readied to enter Phase II/III human clinical trials in the U.S. and Europe. Also in development is EradicAide(TM), a cell mediated, antibody-negative immunotherapeutic/vaccine for HIV Infection/AIDS. In recently completed primate trials EradicAide has shown the ability to reduce HIV viral loads to undetectable levels with no development of viral disease or resistance.
This press release contains forward-looking statements within the meaning of the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
--------------------------------------------------
Contact:
Biokeys Pharmaceuticals Inc., Houston
Warren C. Lau, 281/272-0000
Fax: 281/272-1149
biokeys2@airmail.net
or
Park Avenue Capital, New York
Shirin Kaufman, 212/727-3120
Fax: 212/727-3685
shirin@parkcap.com
SAN DIEGO--(BW HealthWire)--July 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled ``Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome'' has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlinghaus, Ph.D., currently Chair of the Department of Molecular Pathology at The University of Texas M. D. Anderson Cancer Center and formerly Director of Vaccine Development at the Johnson and Johnson Inc. (NYSE:JNJ - news) R.W. Johnson Biotechnology Research Center in La Jolla, Calif. Biokeys Pharmaceuticals Inc. is the exclusive worldwide licensee of this patent and a portfolio of patents and patent applications covering Dr. Arlinghaus' discoveries crucial to the development of a Cell Mediated Immunity vaccine for HIV Infection/AIDS.
Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses its energy in cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. The Company's lead compound, CoFactor(TM), is a chemotherapy biomodulator designed to be used in conjunction with 5-FU, the world's most frequently used cancer drug. CoFactor is being readied to enter Phase II/III human clinical trials in the U.S. and Europe. Also in development is EradicAide(TM), a cell mediated, antibody-negative immunotherapeutic/vaccine for HIV Infection/AIDS. In recently completed primate trials EradicAide has shown the ability to reduce HIV viral loads to undetectable levels with no development of viral disease or resistance.
This press release contains forward-looking statements within the meaning of the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
--------------------------------------------------
Contact:
Biokeys Pharmaceuticals Inc., Houston
Warren C. Lau, 281/272-0000
Fax: 281/272-1149
biokeys2@airmail.net
or
Park Avenue Capital, New York
Shirin Kaufman, 212/727-3120
Fax: 212/727-3685
shirin@parkcap.com
